Nilotinib — Drug Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

4 Recruiting

10 Completed trials

12 Sponsors

19 Countries

Phase III

Phase II

Phase III: 5 Phase II: 7 Phase III/IV: 1 Phase IV: 1 Other: 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Chronic myeloid leukaemia 3 Chronic myeloid leukaemia (in remission) 2

Sponsors using this IMP

Novartis Pharma AG 4 Fondazione Gimema Franco Mandelli Onlus 2 Bluepharma Industria Farmaceutica S.A. 1 Centre Hospitalier Universitaire De Nantes 1 Centre Leon Berard 1 Grupo Espanol De Leucemia Mieloide Cronica (GELMC) 1 Heidelberg University 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Institut National De La Sante Et De La Recherche Medicale 1 Masarykova Univerzita 1 Novartis Farma S.p.A. 1 Radboud universitair medisch centrum Stichting 1

All trials

15 total

Stopping tyrosine kinase inhibitors a second or third time after unsuccesful treatment discontinuation in chronic myeloid leukemia Pending

2024-519472-69-00 Phase II 1 country Heidelberg University
Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME… Recruiting

2024-512696-12-00 Phase II 2 countries Fondazione Gimema Franco Mandelli Onlus; Grupo Espanol De Leucemia Mieloide Cron…
Asciminib Roll-over Study Recruiting

2023-507557-16-00 Phase III 14 countries Novartis Pharma AG
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of… Recruiting

2023-510566-27-00 Phase II 1 country Centre Leon Berard
A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended

2024-516511-24-00 Phase III/IV 1 country Stichting Radboud universitair medisch centrum
AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended

2024-515479-36-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Phase III 10 countries Novartis Pharma AG
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended

2023-508838-33-00 Phase III 15 countries Novartis Pharma AG
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-s… Ended

2024-514592-17-00 Phase II 1 country Masarykova Univerzita
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended

2023-510434-83-00 Phase IV 2 countries Fondazione Gimema Franco Mandelli Onlus
Comparative Bioavailability of Nilotinib 200 mg Hard Capsules in Healthy Subjects. Ended

2022-501325-20-00 1 country Bluepharma Industria Farmaceutica S.A.
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended

2024-514873-22-00 Phase III 1 country Institut National De La Sante Et De La Recherche Medicale
A study of full treatment-free remission in patients with chronic myeloid leukemia Ended

2024-516122-66-00 Phase II 1 country Novartis Farma S.p.A.
Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended

2024-515040-23-00 Phase II 5 countries Novartis Pharma AG

Showing 1–15 of 15 trials

← All drugs A–Z